2025-09-11 08:00
Partnership agreement with Tempus and continued organic growth in the USA
2025-08-22 08:00
The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are hereby invited to the annual general meeting to be held on Tuesday 23 September 2025, at 10.00 CEST at Conference Hubben, Dag Hammarskjölds Väg 38 in Uppsala.
2025-08-13 17:35
NOT TO BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS...
2025-08-05 14:00
NOT TO BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS...
2025-07-25 08:00
Biovica, active in blood-based cancer monitoring, today announces the launch of DiviTum Tka for use in early breast cancer for patients undergoing adjuvant therapy, available as a laboratory developed test (LDT) from its CLIA-certified laboratory in the...
2025-07-24 08:00
Biovica, a leader in blood-based cancer monitoring, today announced its fourth’s work order with this Tier-1 pharmaceutical customer. This order is valued at approximately SEK 3 million. The project is expected to be fully executed during fall 2025...
2025-07-17 10:00
Biovica International AB (publ) ("Biovica" or the "Company") has prepared an information document (the "Information Document") in connection with the Company's fully underwritten rights issue of shares with preferential rights for existing shareholders...
2025-07-14 11:00
Today on 14 July 2025 the extra general meeting of Biovica International AB (the "Company") was held, and the following resolutions were passed by the meeting.
2025-06-27 08:00
Annual Report for the finacial year 2024/2025 for Biovica International AB is published today on our website.
2025-06-26 08:00
Biovica today announced that the European Patent Office (EPO) has granted a new patent for the company’s biomarker technology in the field of immuno-oncology. The patent covers the use of TKa as a marker for predicting the efficacy of immune checkpoint...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects